Interference by antifolate drugs in a folate competitive protein-binding assay

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 552-553

  Hardcastle, Anthea ^a   Clarke, Stephen ^a   Aherne, Wynne ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Antifolate drugs; Protein binding assay

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; 5 METHYLTETRAHYDROFOLIC ACID; FOLIC ACID; FOLIC ACID ANTAGONIST; LOMETREXOL; MILK PROTEIN; NOLATREXED; PEMETREXED; PLEVITREXED; RALTITREXED; UNCLASSIFIED DRUG;

CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN BINDING; RADIOIMMUNOASSAY; SHORT SURVEY; TECHNIQUE;

FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; PROTEIN BINDING; QUINAZOLINES; RADIOIMMUNOASSAY; THIOPHENES;

EID: 0031026794     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050613     Document Type: Short Survey

References (12)

1. Beardsley GP, Moroson BA, Taylor EC, Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate, is a potent inhibitor of de novo purine synthesis. J Biol Chem 264: 328
2. Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR (1996) Phase 1 trial of ZD1694 (Tomudex), a new folate based thymidylate synthase inhibitor. J Clin Oncology 14: 1495
3. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymore L, Lowery K, "Tomudex" Colorectal Cancer Study Group. (1995) Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31A: 1945
4. Duch DS, Banks SD, Dev IK, Dickerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S, Smith GK, Waters K, Wilson HR (1993) Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53: 810
5. Jackman AL and Calvert AH (1995a) Folate-based thymidylate synthase inhibitors as anticancer drugs. Annals Oncol 6: 871
6. Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR (1995b) ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 31A: 1277
7. Jackman AL, Kimbell R, Brown M, Brunton L, Harrap KR, Wardleworth JM, Boyle FT (1995c) The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. In: Sahota A, Taylor M eds. Purine and Pyrimidine Metabolism in Man VIII, Plenum Press, New York, p 185
8. Judson IR, Aherne GW, Maughan T, Cunningham D, Hanwell J, Berry C, Walker M (1996) Pharmacokinetic studies with ZD1694 ("Tomudex"). Annals Oncol 7 (Suppl) 1: 88
9. Lindemans J, Van Kapel J, Abels J (1975) Evaluation of a radioassay for serum folate and the effects of ascorbate and methotrexate. Clin Chim Acta 65: 15
10. Rafi I, Taylor GA, Calvete JA, Boddy AV, Balmanno K, Bailey N, Lind M, Calvert AH, Webber S, Jackson RC, Johnston A, Clendeninn N, Newell DR (1995) Clinical pharmacokinetic and pharmacodynamic studies with the non-classical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous infusion. Clin Cancer Res 1: 1275
11. Rinaldi DA, Burris FA, Dorr FA, Nelson J, Fields SM, Kuhn JG, Eckardt JR, Lu P, Woodworth JR, Corso SW, Hoff DD (1994) A phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 13: 159
12. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM, Jansen G (1995) Carrier- and receptor-mediated transport of folate anatagonists targeting folate-dependent enzymes: Correlates of molecular-structure and biological activity. Mol Pharmacol 48: 459